Last update 24 Dec 2024
EG 427

EG 427

Startups
|
Holding Company|
2019|
France
|
10-50
|
www.eg427.com

Overview

Tags

Urogenital Diseases
Nervous System Diseases
Other Diseases
Gene therapy

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Disease DomainCount
Nervous System Diseases2
Top 5 Drug TypeCount
Gene therapy2

Related

2
Drugs associated with EG 427
EG110A
Target-
Mechanism-
Active Org.
EG 427EG 427Startup
Originator Org.
EG 427EG 427Startup
Active Indication
Neurogenic detrusor overactivity [+4]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
EG-132A
Target-
Mechanism-
Active Org.
EG 427EG 427Startup
Originator Org.
EG 427EG 427Startup
Active Indication
Neuromuscular Diseases
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with EG 427
NCT06596291 / RecruitingPhase 1/2
First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants with Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
100 Clinical Results associated with EG 427
Login to view more data
0 Patents (Medical) associated with EG 427
Login to view more data
100 Deals associated with EG 427
Login to view more data
100 Translational Medicine associated with EG 427
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Phase 2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
EG110A
Neurogenic detrusor overactivity
More
Phase 1/2
EG-132A
Neuromuscular Diseases
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free